HEALTHCARE INSIGHTS
HEALTHCARE INSIGHTS
  • Home
  • #Global Trends
  • #Vietnam
  • #M&A
  • #Regulations
  • #Knowledge
    • #Corporate Wellness
    • #Human Resources
    • #Capability Development
    • #Personal Health
  • Newletter
  • Events
    HEALTHCARE INSIGHTS
    HEALTHCARE INSIGHTS
    • Home
    • #Global Trends
    • #Vietnam
    • #M&A
    • #Regulations
    • #Knowledge
      • #Corporate Wellness
      • #Human Resources
      • #Capability Development
      • #Personal Health
    • Newletter
    • Events

    Category: Uncategorized

    Mass Tort Litigation Defense: Abbott Agrees to $670 Million Settlement to Resolve 2,000 Preterm Infant Formula Necrotizing Enterocolitis (NEC) Claims

    21/08/2026 Published by Pharma Biz

    Key Development On August 20, 2026, global healthcare leader Abbott Laboratories (NYSE: ABT) formally announced a $670 million comprehensive settlement... Read more

    Category: Uncategorized
    Tags: #Global Trends

    Breakthrough in Personalized Oncology: Moderna and Merck’s Tailored mRNA Cancer Vaccine Intismeran Cuts Melanoma Recurrence and Metastasis in Landmark Phase 3 Trial – Moderna Shares Surge 160%

    20/08/2026 Published by Pharma Biz

    Key Development On August 19, 2026, Moderna (NASDAQ: MRNA) and Merck & Co. (NYSE: MRK) announced positive interim results from... Read more

    Category: Uncategorized
    Tags: #Global Trends

    CNS Patent Defense & Market Exclusivity: SK Biopharmaceuticals Reaches Landmark Patent Settlement with MSN Laboratories to Protect U.S. Exclusivity for Anti-Epileptic Blockbuster Xcopri® (Cenobamate) Beyond 2032

    20/08/2026 Published by Pharma Biz

    Key Development On August 19, 2026, South Korean biopharmaceutical leader SK Biopharmaceuticals (KRX: 326030) formally concluded its first patent litigation... Read more

    Category: Uncategorized
    Tags: #Global Trends

    Ultrarare Genetic Disease Milestone: FDA Approves Regeneron’s Pasatru® (Garetosmab) for Fibrodysplasia Ossificans Progressiva (FOP) – Delivering Up to 94% Reduction in New Heterotopic Bone Lesions

    20/08/2026 Published by Pharma Biz

    Key Development Following more than a decade of translational R&D, Regeneron Pharmaceuticals (NASDAQ: REGN) has secured landmark regulatory approval from... Read more

    Category: Uncategorized
    Tags: #Global Trends

    Health Supplement Advertising Compliance: Vietnam Food Safety Authority Mandates Urgent Hanoi Health Department Inspection into DK-Betics Gold for Misleading Curative Claims and Physician Imagery

    20/08/2026 Published by Pharma Biz

    Key Development On the evening of August 19, 2026, the Vietnam Food Safety Authority (VFA) under the Ministry of Health... Read more

    Category: Uncategorized
    Tags: #Vietnam

    Digital Health Marketing Enforcement: Vietnam Food Safety Authority Directs Hanoi Department of Health to Audit Misleading Advertising for DK-Betics Gold and Non Alco Lozenges

    20/08/2026 Published by Pharma Biz

    Key Development The Vietnam Food Safety Authority (VFA) under the Ministry of Health has officially issued an urgent regulatory directive... Read more

    Category: Uncategorized
    Tags: #Vietnam

    Global Infectious Disease Licensing: Chugai Grants GSK Exclusive Worldwide License for Investigational Anti-Dengue Antibody AID351

    19/08/2026 Published by Pharma Biz

    Key Development Tokyo-headquartered biopharmaceutical enterprise Chugai Pharmaceutical Co., Ltd. (TYO: 4519)—a member of the Roche Group—has officially entered into an... Read more

    Category: Uncategorized
    Tags: #M&A

    Targeting Undruggable Ion Channels: Eli Lilly and OmniAb Enter Global Research Collaboration and License Agreement Valued Up to $370 Million for Next-Generation Antibody Therapeutics

    19/08/2026 Published by Pharma Biz

    Key Development Global biopharmaceutical leader Eli Lilly and Company (NYSE: LLY) has formally executed a global collaboration and license agreement... Read more

    Category: Uncategorized
    Tags: #M&A

    Rare Skeletal Disease M&A: BioMarin Acquires Alesta Therapeutics for Up to $490 Million to Challenge AstraZeneca’s Hypophosphatasia Franchise with Oral Asset ALE1

    19/08/2026 Published by Pharma Biz

    Key Development Rare disease biopharmaceutical leader BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has entered into a definitive agreement to acquire clinical-stage... Read more

    Category: Uncategorized
    Tags: #M&A

    Posts pagination

    Previous page Page 1 … Page 35 Page 36 Page 37 … Page 225 Next page

    Facebook

    Map

    Workday: Monday to Friday
    Working hours: 8am to 5pm
    Address: 8th floor, Hyco 4 building, 205A Nguyen Xi Street, Binh Thanh Ward, HCMC

    Please enable JavaScript in your browser to complete this form.
    Get Your Weekly Market Insights Stay informed on Vietnam's market & Healthcare Alliance updates
    Loading

    Online Members

    Recent Comments

    • GauTruc on New Biotech Startup Secures $125 Million to Advance Pain Medication
    HEALTHCARE INSIGHTS
    All rights reserved